Pucotenlimab

DB17552ApprovedInvestigationalProtein Based Therapies

Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours. It is being investigated in...

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Also known as: Humanized pd-1 blocking antibody hx-008 · Immunoglobulin g4 (252-theronine,306-proline,432-alanine), anti-(human programmed cell death 1) (human-mus musculus monoclonal hx008 .gamma.4-chain), disulfide with human-mus musculus monoclonal hx008 .kappa.-chain, dimer
Code names: HX-008

Resolves to

Compound

UNIICGA81G3KR5CAS2403647-03-8

Targets

Q15116PDCD1

What you can answer from here — as of September 05, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

72Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pucotenlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account